NASDAQ:TEM 8 October 2025 - 25 February 2026

Tempus AI shares fell 4.1% to $55.59 in premarket trading after the company set 2026 revenue guidance at $1.59 billion and projected adjusted EBITDA of $65 million. Fourth-quarter revenue jumped 83% to $367.2 million, with MRD test volume up 56% to about 4,700. The company still posted a net loss and relied on stock-based compensation. The stock closed Tuesday at $57.95.

Tempus AI shares closed near $76.70 on December 5, 2025, up 52% from a year earlier, with a market cap around $13.6 billion. The stock trades at a forward price-to-sales ratio of 8–10x and a negative P/E near –65. Recent analyst notes and institutional buying have fueled debate over valuation as volatility remains high. Tempus went public in June 2024 and focuses on AI-driven precision medicine.